1. Home
  2. GIPR vs GNPX Comparison

GIPR vs GNPX Comparison

Compare GIPR & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generation Income Properties Inc.

GIPR

Generation Income Properties Inc.

HOLD

Current Price

$0.95

Market Cap

6.4M

Sector

Real Estate

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.84

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIPR
GNPX
Founded
2015
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
6.5M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
GIPR
GNPX
Price
$0.95
$2.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
702.2K
330.9K
Earning Date
11-17-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,953,920.00
N/A
Revenue This Year
$1.12
N/A
Revenue Next Year
$0.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$2.51
52 Week High
$2.06
$63.00

Technical Indicators

Market Signals
Indicator
GIPR
GNPX
Relative Strength Index (RSI) 45.65 42.33
Support Level $0.89 $3.15
Resistance Level $1.34 $3.68
Average True Range (ATR) 0.14 0.28
MACD 0.03 0.00
Stochastic Oscillator 26.44 28.21

Price Performance

Historical Comparison
GIPR
GNPX

About GIPR Generation Income Properties Inc.

Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: